OOIR: Observatory of International Research

Papers

(The H4-Index of RMD Open is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
CD73^low B-cell phenotypes and distinct cytokine profiles in patients with active anti-Jo-1 antibody positive idiopathic inflammatory myopathies	192
Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism	90
Assessment and personalised advice for fatigue in systemic lupus erythematosus using an innovative digital tool: the Lupus Expert system for the Assessment of Fatigue (LEAF) study	85
Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study	81
Correction: Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider	66
Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study	65
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination	63
Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use	61
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry	56
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 tri	52
Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritis	51
Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry	48
Antirheumatic treatment, disease activity and risk ofStaphylococcus aureusbacteraemia in rheumatoid arthritis: a nationwide nested case–control study	46
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2	45
Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study	45
Declaration on the use of social media for rheumatology professionals	43
Social media in advancing equity and collaboration in rheumatology: the CORDIALITY review	42
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study	41
Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupu	41
Identification of variants in genes associated with autoinflammatory disorders in a cohort of patients with psoriatic arthritis	41
Concordance and agreement between different activity scores in polymyalgia rheumatica	41
Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study	41
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cr	40
Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan	39
Optical coherence tomography angiography detects retinal microvascular changes in giant cell arteritis: the potential protective role of aortitis	38

Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study	38
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis	38
PD1 ⁺ TIGIT ⁺ CD4 ⁺ T cells predict response to	38
Chronic abdominal aortic occlusive disease related to antiphospholipid syndrome: a rare presentation	37
Trends in work participation among patients with inflammatory rheumatic musculoskeletal diseases (iRMDs): Data from the German National Database (2010–2022)	37
Machine learning using genotype and gene-expression data identifies alterations of genes involved in infection susceptibility, antigen presentation and cytokine signalling as key contributors to JIA r	37
History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis	37
Bilateral swelling of the salivary glands and sicca symptoms: an unusual differential diagnosis—Kimura’s disease, a rare allergic condition with a high IgE serum level—a case report and review of the	36
Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study	36
Engagement and attrition with eHealth tools for remote monitoring in chronic arthritis: a systematic review and meta-analysis	36
Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis	36